Mafosfamide — A Derivative of 4-Hydroxycyclophosphamide

  • Ulf Niemeyer
  • Jürgen Engel
  • Peter Hilgard
  • Manfred Peukert
  • Jörg Pohl
  • Herbert Sindermann
Part of the Progress in Clinical Biochemistry and Medicine book series (PCBM, volume 9)

Abstract

The chemical development of mafosfamide (MA)-L-lysine salt as a “stabilized” prodrug of 4-hydroxyCP, i.e. the solid-state unstable primary metabolite of the anticancer drug cyclophosphamide (CP), involved a stereoselective synthesis and an optimized cation exchange with subsequent lyophilization. The stereochemical and physicochemical characterization of MA elucidated further the complex metabolic behavior of oxazaphosphorine cytostatics and confirmed imino-CP as a transient primary intermediate.

Keywords

Hydrolysis Leukemia Oncol Disulfide Thiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brock N (1983) Oxazaphosphorine cytostatics: structure-activity relationships, selectivity and metabolism, regional detoxification. In Reinhoudt DN, Connors TA, Pinedo HM, van de Poll KW (eds) Structure-activity relationships of anti-tumor agents. Developments in pharmacology 3; Martinus Nijhoff, The Hague, p 239CrossRefGoogle Scholar
  2. 2.
    Brock N., Hohorst H-J (1963) Arzneim.-Forsch./Drugs Res. 13: 1021Google Scholar
  3. 3.
    Hohorst H-J, Ziemann A., Brock N (1971) Arzneim.-Forsch./Drug Res. 21: 1254Google Scholar
  4. 4.
    Brock N, Hohorst H-J (1977) Z. Krebsforsch. 88: 185CrossRefGoogle Scholar
  5. 5.
    Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979) Arzneim.-Forsch./Drug Res. 29: 659Google Scholar
  6. 6.
    Brock N (1980) New experience with the oxazaphosphorines with special reference to the uro-protector Uromitexan. In: Burkert H, Nagel GA (eds) Contributions to Oncology 5; S. Karger, Basel, p 1Google Scholar
  7. 7.
    Borch RF, Hoye TR, Swanson TA (1984) J. Med. Chem. 27: 490CrossRefGoogle Scholar
  8. 8.
    Voelcker G., Draeger U, Peter G, Hohorst H-J (1974) Arzneim.-Forsch./Drug Res. 24: 1172Google Scholar
  9. 9.
    Friedman OM, Myles A, Colvin M (1979) Cyclophosphamide and related phosphoramide mustards: current status and future prospects. In: Rosowsky A (ed) Advances in Cancer Chemother., Dekker, New York, p 143Google Scholar
  10. 10.
    Friedman OM (1967) Cancer Chemother. Rep 51: 347Google Scholar
  11. 11.
    Engle TW, Zon G, Egan W (1979) J. Med. Chem. 22: 897CrossRefGoogle Scholar
  12. 12.
    Grunicke H, Doppler W, Hofmann J, Lindner H, Maly K, Oberhuber H, Ringsdorf H, Roberts JJ (1986) Advances in Enzyme Regul. 24: 247CrossRefGoogle Scholar
  13. 13.
    Wrabetz E, Peter G, Hohorst H-J (1980) J. Cancer Res. Clin. Oncol. 98: 119CrossRefGoogle Scholar
  14. 14.
    Watson E, Phoebe D, Chan KK (1985) J. Pharm. Sci. 74: 1283CrossRefGoogle Scholar
  15. 15.
    Draeger U, Hohorst H-J (1976) Cancer Treat. Rep. 60: 423Google Scholar
  16. 16.
    Lenssen U, Hohorst H-J (1979) J. Cancer Res. Clin. Oncol. 93: 161CrossRefGoogle Scholar
  17. 17.
    Boyd VL, Robbins JD, Egan W, Ludeman SM (1986) J. Med. Chem. 29: 1206CrossRefGoogle Scholar
  18. 18.
    Zon G, Ludeman SM, Sweet EM, Egan W, Phillips LR (1982) J. Pharm. Sci. 71: 443CrossRefGoogle Scholar
  19. 19.
    Sladek NE (1973) Cancer Res. 33: 651Google Scholar
  20. 20.
    Zon G, Ludeman SM, Brandt JA, Boyd VL, Özkan G, Egan W (1984) J. Med. Chem. 27: 466CrossRefGoogle Scholar
  21. 21.
    Borch RF, Gutman KM (1984) J. Med. Chem. 27: 485CrossRefGoogle Scholar
  22. 22.
    Draeger U, Peter G, Hohorst H-J (1976) Cancer Treat. Rep. 60: 355Google Scholar
  23. 23.
    Low JE, Borch RF, Sladek NE (1983) Cancer Res. 43: 4815Google Scholar
  24. 24.
    Bielicki L., Voelcker G, Hohorst H-J (1984) J. Cancer Res. Clin. Oncol. 107: 195CrossRefGoogle Scholar
  25. 25.
    Connors TA, Cox PJ, Farmer PB, Foster AB, Jarman M (1974) Biochem. Pharmacol. 23: 115CrossRefGoogle Scholar
  26. 26.
    Brock N, Stekar J, Pohl J, Scheef W (1979) Naturwissenschaften 66: 60CrossRefGoogle Scholar
  27. 27.
    Scheef W, Klein HO, Brock N, Burkert H, Günther U, Hoefer-Janker H, Mitrenga D, Schnitker J, Voigtmann R (1979) Cancer Treat. Rep. 63: 501Google Scholar
  28. 28.
    Brock N, Hilgard P, Pohl J, Ormstad K, Orrenius S (1984) J. Cancer Res. Clin. Oncol. 108: 87CrossRefGoogle Scholar
  29. 29.
    Cox PJ (1979) Eur. J. Cancer 15: 1071CrossRefGoogle Scholar
  30. 30.
    Brock N (1986) J. Cancer Res. Clin. Oncol. 111: 1CrossRefGoogle Scholar
  31. 31.
    Peter G, Hohorst H-J (1979) Cancer Chemother. Pharmacol. 3: 181Google Scholar
  32. 32.
    Ramonas LM, Erickson LC, Ringsdorf H, Zaharko DS (1980) Cancer Res. 40: 3704Google Scholar
  33. 33.
    Takamizawa A, Matsumoto S, Iwata T, Kentagiri K, Tochino Y, Yamaguchi K (1973) J. Amer. Chem. Soc. 95: 985CrossRefGoogle Scholar
  34. 34.
    Peter G, Wagner T, Hohorst H-J (1976) Cancer Treat. Rep. 60: 429Google Scholar
  35. 35.
    Niemeyer U, Engel J, Scheffler G, Molge K, Sauerbier D, Weigert W (1984) Invest. New Drugs 2: 133CrossRefGoogle Scholar
  36. 36.
    Niemeyer U, Engel J, Scheffler G, Pohl J, Hägele G, Krebs B (1987) Phosphorus and Sulphur 30: 585Google Scholar
  37. 37.
    White DW, Gibbs DE, Verkade JG (1979) J. Amer. Chem. Soc. 101: 1937CrossRefGoogle Scholar
  38. 38.
    Setzer WN, Sopchick AE, Bentrude WG (1985) J. Amer. Chem. Soc. 107: 2083CrossRefGoogle Scholar
  39. 39.
    Domeyer BE, Sladek NE (1980) Biochem. Pharmacol: 29: 2903Google Scholar
  40. 40.
    Molge K (1983) Characterization of the hydrolysis of mafosfamide. ASTA Pharma AG, Research Report no. 53Google Scholar
  41. 41.
    Kwon C-H, Borch RF, Engel J, Niemeyer U (1987) J. Med. Chem. 30: 395CrossRefGoogle Scholar
  42. 42.
    Niemeyer U, Engel J, Meyer zur Heyde M, Molge K, Wolf-Heuss E (1987) International Symposium on pharmaceutical and biomedical analysis, Barcelona, p 244Google Scholar
  43. 43.
    Niemeyer U (1978) TLC-determination of mafosfamide and metabolites in urine samples. ASTA Pharma AGGoogle Scholar
  44. 44.
    Pohl J, Hilgard P, Jahn W, Zechel H-J (1984) Invest. New Drugs 2: 201CrossRefGoogle Scholar
  45. 45.
    Manz I, Dietrich I, Przybylski M, Niemeyer U, Pohl J, Hilgard P, Brock N (1985) Biomed. Mass Spectrometry 12: 545CrossRefGoogle Scholar
  46. 46.
    Ludeman SM (1986) Personal communicationGoogle Scholar
  47. 47.
    Burton LC, Harper PG, James CA, Rogers HJ, Liang R (1985) The clinical trial and pharmacokinetics of 4-hydroxycyclophosphamide and mesna derived from mafosfamide (ASTA Z 7557) and its comparison with other oxazaphosphorines in man. Report to Cancer Research CampaignGoogle Scholar
  48. 48.
    Osieka R, Pannenbächer R, Schmidt CG (1984) Invest. New Drugs 2: 161CrossRefGoogle Scholar
  49. 49.
    Berger MR, Bedford P, Zeller WJ, Kaufmann M (1984) Invest. New Drugs 2: 181CrossRefGoogle Scholar
  50. 50.
    Huang AT, Kremer WB, Laszlo J, Setlow RB (1972) Nature New Biol. 240: 114Google Scholar
  51. 51.
    Grunicke H, Gruenwald K, Heiliger W, Scheidl F, Wolf-Schreiner E, Puschendorf B (1983) Adv. in Enzyme Regul. 21: 21CrossRefGoogle Scholar
  52. 52.
    Askenase PW, Hayden BJ, Gershon RK (1975) J. Exp. Med. 141: 697CrossRefGoogle Scholar
  53. 53.
    L’Age-Stehr J, Diamantstein T (1978) Nature 271: 663CrossRefGoogle Scholar
  54. 54.
    Brock N, Niemeyer U, Pohl J, Scheffler G (1981) Third NCI-EORTC symposium on new drugs in cancer therapy, No. 47, BrusselsGoogle Scholar
  55. 55.
    Pohl J (1984) Mafosfamide - Summary for Investigators. Asta Pharma AGGoogle Scholar
  56. 56.
    Atassi G, Hilgard P, Pohl J (1984) Invest. New Drugs 2: 169CrossRefGoogle Scholar
  57. 57.
    Brock N, Hilgard P, Peukert M, Pohl J, Sindermann H (1989) Cancer Invest.Google Scholar
  58. 58.
    Klein HO, Wickramanayake PD, Christian E, Coerper C (1984) Invest. New Drugs 2: 191CrossRefGoogle Scholar
  59. 59.
    Zeller WJ, Berger MR, Matys R, Schumacher J (1984) Invest. New Drugs 2: 175CrossRefGoogle Scholar
  60. 60.
    Kleine W, Düser B, Runge M, Grezes IR, Kröger H, Klosa J (1984) J. Cancer Res. Clin. Oncol. 107: 80Google Scholar
  61. 61.
    Osieka R, Glatte P, Bamberg M, Scherer E, Schmidt CG (1984) Proc. Am. Ass. Canc. Res. 25: 330Google Scholar
  62. 62.
    Nowrousian MR, Schmidt CG (1984) Invest. New Drugs 2: 207CrossRefGoogle Scholar
  63. 63.
    Hilgard P, Pohl J (1986) Invest. New Drugs 4: 373CrossRefGoogle Scholar
  64. 64.
    Bruntsch U, Groos G, Hiller TA, Wandt H, Tigges FJ, Gallmeier WM (1985) Invest. New Drugs 3: 297CrossRefGoogle Scholar
  65. 65.
    Bruntsch U, Groos U, Hiller TA, Wandt H, Tigges FJ, Gallmeier WM (1984) Cancer Immunol. Immunother. 18: 11Google Scholar
  66. 66.
    Abele R, Aapro MS, Haeflinger JM, Alberto P (1986) Cancer Chemother. Pharmacol. 16: 182Google Scholar
  67. 67.
    Peukert M (1984) Preliminary clinical evaluation of mafosfamide. ASTA Pharma AGGoogle Scholar
  68. 68.
    Peukert M (1985) Phase-I studies with mafosfamide. ASTA Pharma AGGoogle Scholar
  69. 69.
    Voelcker G, Laber P, Rockinger H, Wientzek C, Hohorst HJ (1984) Invest. New Drugs 2: 253CrossRefGoogle Scholar
  70. 70.
    Friedl P, Berger MR, Rozycki-Gerlach W, Schlag P, Schmähl D (1988) J. Cancer Clin. Res. Oncol. 114, Suppl. S 187Google Scholar
  71. 71.
    Bartkowski R, Berger MR, Aguiar JLA, Henne TH, Dörsam J, Geelhaar GH, Schlag P, Herfarth C (1986) J. Cancer Res. Clin. Oncol. 111:.42Google Scholar
  72. 72.
    Wagner T, Walter E, Mittendorf F, Voelcker G (1984) J. Cancer Res. Clin. Oncol. 107: 46Google Scholar
  73. 73.
    Hamburger AW, Salmon SE (1977) Science 197: 461CrossRefGoogle Scholar
  74. 74.
    Alberts DC, Einspahr JG, Struck R, Bignami G, Young L, Surwit EA, Salmon SE (1984) Invest. New Drugs 2: 141CrossRefGoogle Scholar
  75. 75.
    Einspahr J, Alberts DS, Struck R, Salmon SE (1984) Proc. Am. Soc. Clin. Oncol. 25: 38Google Scholar
  76. 76.
    Kaufmann M (1986) Personal communicationGoogle Scholar
  77. 77.
    Buse KD, Kaufmann M, Kubli F (1985) Der biochemische Kurzzeit-Inkubations-Assay zur In-vitro Chemoresistenztestung und als Prognosefaktor bei menschlichen Tumoren. In: Jonat W, Kaufmann M, Kubli F et al. (eds) Aktuelle Onkologie 16, Zuckerschwerdt, MünchenGoogle Scholar
  78. 78.
    Sharkis SJ, Santos GW, Colvin M (1980) Blood 55: 521Google Scholar
  79. 79.
    Körbling M, Hess AD, Tutschka PJ, Kaizer H, Colvin M, Santos GW (1982) Brit. J. Hematol. 52: 89CrossRefGoogle Scholar
  80. 80.
    Kohn FR, Sladek NE (1984) Proc. Am. Ass. Canc. Res. 25: 289Google Scholar
  81. 81.
    Aglietta M, Stacchini A, Sanavio F, Piacibello W, Gavosto F (1987) Bone Marrow Transpl. 2: 56Google Scholar
  82. 82.
    Douay L, Gorin NC, Laporte J-P, Lopez M, Najman A, Duhamel G (1984) Invest. New Drugs 2: 187CrossRefGoogle Scholar
  83. 83.
    Hagenbeek A, Martens ACM (1984) Invest. New Drugs 2: 237CrossRefGoogle Scholar
  84. 84.
    Hervé P, Cahn JY, Plouvier E, Flesch M, Tamayo E, Leconte des Floris R, Peters A (1984) Invest. New Drugs 2: 245Google Scholar
  85. 85.
    Hervé P, Tamayo E, Cahn W, Plouvier E, Flesch M, Peters A (1986) Attempts to eliminate residual acute myeloid leukemia from autologous bone marrow grafts through in vitro chemotherapy - a review. In: Hagenbeck A, Loewenberg B (eds) Minimal residual disease in leukemia, Martinus Nijhoff, Dordrecht, p 248CrossRefGoogle Scholar
  86. 86.
    Hervé P, Plouvier E, Amsallen D, Racadot E, Noir A (1987) Bone Marrow Transpl. 2: 53Google Scholar
  87. 87.
    LeBien TW, Anderson JM, Vallera A, Uckun FM (1986) Leukemia Res. 10: 139CrossRefGoogle Scholar
  88. 88.
    Uckun FM, Ramakrishnan S, Houston LL (1985) Blood 50: 19Google Scholar
  89. 89.
    Uckun FM, Ramakrishnan S, Haag D, Houston LL (1985) Leukemia Res. 9: 83CrossRefGoogle Scholar
  90. 90.
    Uckun FM, Stong RC, Youle RJ, Vallera DA (1985) J. Immunol. 134: 3504Google Scholar
  91. 91.
    Porcellini A, Marchetti Rossi MT, Centis F, Manna A, Talevi N, Agostini A, Pazzaglia C (1987) Bone Marrow Transpl. 2: 52Google Scholar
  92. 92.
    Flesch M, Hervé P (1985) Blood Transfus. Immunohaemat. 28: 489CrossRefGoogle Scholar
  93. 93.
    Rizzoli V, Mangoni L, Carella AM, Torlontano G, Aglietta M, Mozana R, Porcellini A, Cole-selli P (1987) Exp. Hemat. Today (in press)Google Scholar
  94. 94.
    Gorin NC, Aegerter P (1987) Bone Marrow Transpl. 2: 320Google Scholar
  95. 95.
    Körbling M, Ho A, Dörken B, Haas R, Pezzutto A, Martin H, Deboben A, Reichardt P, Tischbirek K, Mende U, Fehrentz D, Hunstein W (1987) Bone Marrow Transpl. 2: 62Google Scholar
  96. 96.
    Laporte JP, Gorin NC, Douay L, Lopez M, Bauters F, Jouet JP, Walter MP, Lemonnier MP, Salmon C, Najman A (1987) Bone Marrow Transpl. 2: 61Google Scholar
  97. 97.
    Gorin NC, Hervé P, Aegerter P, Goldstone A, Linch D, Maraninchi D, Burnett A, Helbig W (1986) Brit. J. Haematol. 64: 385CrossRefGoogle Scholar
  98. 98.
    Potei J, Brock N (1971) Arzneim.-Forsch./Drug Res. 21: 1250Google Scholar
  99. 99.
    Scheper RJ, Vos A, de Groot J, Boerrigter GH (1984) Invest. New Drugs 2: 221CrossRefGoogle Scholar
  100. 100.
    Mitsuoka A, Baba M, Morikawa S (1976) Nature 262: 77CrossRefGoogle Scholar
  101. 101.
    Turk JL, Parker D: The effect of drugs on immunological control mechanisms. In: Turk JL, Parker D (eds) Drugs and immune responsiveness, Macmillan, London, p 73Google Scholar
  102. 102.
    Ozer H, Cowens JW, Nussbaum A, Mihich E, Colvin M (1981) Fed. Proc. 40: 1075Google Scholar
  103. 103.
    Brock N (1978) Pharmakologische Grundlagen der Krebs-Chemotherapie. In: Georgii A (ed) Verhandlungen der Deutschen Krebsgesellschaft. Band 1, 13. Deutscher Krebskongreß Hamburg 1976. Gustav Fischer, Stuttgart, p 15Google Scholar
  104. 104.
    Hilgard P, Pohl J, Stekar J, Voegeli R (1985) Cancer Treatm. Rev. 12, 155Google Scholar
  105. 105.
    Cowens JW, Ozer H, Ehrke J, Colvin M, Mihich E (1981) Fed. Proc. 40: 1086Google Scholar
  106. 106.
    Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H (1982) Cancer Res. 42: 4862Google Scholar
  107. 107.
    Duclos H, Galanaud P, Devinsky O, Maillot MC, Dormont J (1977) Eur. J. Immunol. 7: 679CrossRefGoogle Scholar
  108. 108.
    Hengst JCD, Mokyr MB, Dray S (1980) Cancer Res. 40: 2135Google Scholar
  109. 109.
    Mokyr MB, Hengst JC, Dray S (1982) Cancer Res. 42: 974Google Scholar
  110. 110.
    Voegeli R, Pohl J, Reissmann T, Stekar J, Hilgard P (1986) Therapeutic efficacy of oxazaphosphorines by immunomodulation. In: Chandra P (ed) New Experimental modalities in the control of neoplasia. Plenum, p 243Google Scholar
  111. 111.
    Mokyr MB, Brundrett RB, Colvin M, Dray S (1986) Cancer Res. 46: 3313Google Scholar
  112. 112.
    Klein HO, Kreysch H-G, Coerper C, Voigt P, Ruff I (1987) Meth. and Find. Exptl. Clin. Pharmacol. 9: 627Google Scholar
  113. 113.
    Klein HO, Kreysch H-G, Coerper C, Voigt P (1988) J. Cancer Res. Clin. Oncol. 114,’Suppl. S 126Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • Ulf Niemeyer
    • 1
  • Jürgen Engel
    • 1
  • Peter Hilgard
    • 1
  • Manfred Peukert
    • 1
  • Jörg Pohl
    • 1
  • Herbert Sindermann
    • 1
  1. 1.ASTA Pharma AGBielefeld 14Germany

Personalised recommendations